Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT ID: NCT04493853
Last Updated: 2026-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
1012 participants
INTERVENTIONAL
2020-07-13
2027-03-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
NCT04087174
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
NCT01715285
A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
NCT01695135
Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
NCT01485861
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
NCT00887198
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Capivasertib + Abiraterone
Participants receive capivasertib in combination with abiraterone (prednisone/prednisolone) on a background of ADT.
Capivasertib
400 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
Abiraterone Acetate
Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.
Placebo + Abiraterone
Participants receive placebo in combination with abiraterone (prednisone/prednisolone) on a background of ADT.
Placebo
matched to capivasertib appearance (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
Abiraterone Acetate
Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Capivasertib
400 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
Placebo
matched to capivasertib appearance (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
Abiraterone Acetate
Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Consent to provide a FFPE tissue block (preferred) or slides. Tissue from bone metastases is not acceptable
* A valid PTEN IHC result indicating PTEN deficiency (centralized testing)
* Metastatic disease documented prior to randomisation by clear evidence of ≥ 1 bone lesion and/or ≥ 1 soft tissue lesion accurately assessed at baseline and suitable for repeated assessment with CT and/or MRI. PSMA PET identification only will not be eligible
* Candidate for abiraterone and steroid therapy
* Ongoing ADT with GnRH analogue, or LHRH agonists or antagonist, or bilateral orchiectomy (regardless of method) is from 0 days to a max. of 93 days prior to randomisation
* Eastern Cooperative Oncology Group (ECOG)/WHO performance status 0 to 1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks
* Able and willing to swallow and retain oral medication
* 7-day Brief Pain Inventory-Short Form (BPI-SF) and Brief Fatigue Inventory(BFI) questionnaires and the analgesic diary during screening completed. Participants must complete a minimum of 4 successful assessments within a 7-day period prior to randomisation.
* Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm
* Capable of giving signed informed consent
* Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of samples
Exclusion Criteria
* Major surgery (excluding placement of vascular access, transurethral resection of prostate, bilateral orchiectomy, or internal stents) within 4 weeks of the start of study treatment
* Brain metastases, or spinal cord compression (unless spinal cord compression is asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment)
* Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
* Any of the following cardiac criteria:
i. Mean resting corrected QT interval (QTc) \> 470 msec obtained from triplicate ECGs ii. History of QT prolongation associated with other medications that required discontinuation of that medication.
iii. Family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives.
iv. Medical history significant for arrhythmia which is symptomatic or requires treatment, symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia.
v. Any clinically important abnormalities in conduction or morphology of resting ECG (eg, complete left bundle branch block, third-degree heart block) vi. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as hypokalaemia, potential for torsades de pointes, congenital long QT syndrome, or any concomitant medication known to significantly prolong the QT interval vii. Experience of any of the following procedures or conditions in the preceding 3 months: coronary artery bypass graft, angioplasty, myocardial infarction, angina pectoris.
viii. Congestive heart failure NYHA Grade ≥ 2 ix. Symptomatic hypotension - systolic blood pressure (SBP) \<90 mmHg and/or diastolic blood pressure (DBP) \<50 mmHg x. Uncontrolled hypertension (SBP ≥ 160 mmHg or DBP ≥ 95 mmHg).
* Clinically significant abnormalities of glucose metabolism as defined by any of the following:
i. Patients with diabetes mellitus type 1 or diabetes mellitus type 2 requiring insulin treatment ii. HbA1c ≥8.0% (63.9 mmol/mol)
* Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
i. Absolute neutrophil count \< 1.5x 10\^9/L ii. Platelet count \< 100x 10\^9/L iii. Haemoglobin \< 9 g/dL (\< 5.59 mmol/L) iv. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \> 2.5x upper limit of normal (ULN) if no demonstrable liver metastases or \> 5x ULN in the presence of liver metastases. Elevated alkaline phosphatase (ALP) is not exclusionary if due to the presence of bone metastases and liver function is otherwise considered adequate in the investigator's judgement v. Total bilirubin \> 1.5x ULN (participants with confirmed Gilbert's syndrome may be included in the study with a higher value) vi. Creatinine clearance \< 50 mL/min (measured or calculated by Cockcroft and Gault equation)
* As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or known active infection including hepatitis B, hepatitis C, and HIV
* unevaluable for both bone and soft tissue progression as defined by meeting both of the following criteria: i. a "superscan" of bone scan, and ii. no soft tissue lesion that can be assessed by RECIST criteria
* Refractory nausea and vomiting, malabsorption syndrome, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection, or other condition that would preclude adequate absorption of capivasertib
* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent
* Evidence of dementia, altered mental status, or any psychiatric condition that would prohibit understanding or rendering of informed consent
* Previous allogeneic bone marrow transplant or solid organ transplant
* History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease.
* Treatment with any of the following:
i. Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment ii. Any investigational agents or study drugs from a previous clinical study within 30 days or 5 half-lives (whichever is longer) of the first dose of study treatment iii. Any other chemotherapy, immunotherapy, immunosuppressant medication (other than corticosteroids) or anticancer agents within 3 weeks of the first dose of study treatment. A longer washout may be required for drugs with a long half-life (eg, biologics) iv. Strong inhibitors or strong inducers of CYP3A4 within 2 weeks before the start of study treatment (3 weeks for St John's wort). Note that adequate washout or dose reduction may be required for some CYP3A substrates prior to initiating Capivasertib dosing.
* Drugs known to significantly prolong the QT interval and associated with Torsades de Pointes within 5 half-lives of the first dose of study treatment
* Participation in another clinical study with an investigational product administered in the last 30 days or 5 half-lives, whichever is longer.
* History of hypersensitivity to active or inactive excipients of capivasertib, abiraterone, or drugs with a similar chemical structure or class.
* Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
* Any restriction or contraindication based on the local prescribing information that would prohibit the use of abiraterone.
18 Years
130 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Tucson, Arizona, United States
Research Site
Tucson, Arizona, United States
Research Site
La Jolla, California, United States
Research Site
Orange, California, United States
Research Site
San Diego, California, United States
Research Site
Denver, Colorado, United States
Research Site
Lakewood, Colorado, United States
Research Site
Norwich, Connecticut, United States
Research Site
Fort Myers, Florida, United States
Research Site
West Palm Beach, Florida, United States
Research Site
Chicago, Illinois, United States
Research Site
Geneva, Illinois, United States
Research Site
Lisle, Illinois, United States
Research Site
Baltimore, Maryland, United States
Research Site
Detroit, Michigan, United States
Research Site
Grand Rapids, Michigan, United States
Research Site
Troy, Michigan, United States
Research Site
Syracuse, New York, United States
Research Site
The Bronx, New York, United States
Research Site
Asheville, North Carolina, United States
Research Site
Durham, North Carolina, United States
Research Site
Columbus, Ohio, United States
Research Site
Lancaster, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Charleston, South Carolina, United States
Research Site
Myrtle Beach, South Carolina, United States
Research Site
Chattanooga, Tennessee, United States
Research Site
Houston, Texas, United States
Research Site
Norfolk, Virginia, United States
Research Site
Roanoke, Virginia, United States
Research Site
Seattle, Washington, United States
Research Site
Madison, Wisconsin, United States
Research Site
Berazategui, , Argentina
Research Site
Buenos Aires, , Argentina
Research Site
CABA, , Argentina
Research Site
CABA, , Argentina
Research Site
Ciudad de Buenos Aires, , Argentina
Research Site
Ciudad de Buenos Aires, , Argentina
Research Site
La Plata, , Argentina
Research Site
Mendoza, , Argentina
Research Site
Rosario, , Argentina
Research Site
San Salvador de Jujuy, , Argentina
Research Site
Birtinya, , Australia
Research Site
Darlinghurst, , Australia
Research Site
Kingswood, , Australia
Research Site
Orange, , Australia
Research Site
South Brisbane, , Australia
Research Site
Graz, , Austria
Research Site
Linz, , Austria
Research Site
Salzburg, , Austria
Research Site
Anderlecht, , Belgium
Research Site
Ghent, , Belgium
Research Site
Kortrijk, , Belgium
Research Site
Liège, , Belgium
Research Site
Belém, , Brazil
Research Site
Belo Horizonte, , Brazil
Research Site
Florianópolis, , Brazil
Research Site
Fortaleza, , Brazil
Research Site
Jaú, , Brazil
Research Site
Joinville, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Ribeirão Preto, , Brazil
Research Site
Rio de Janeiro, , Brazil
Research Site
Santa Maria, , Brazil
Research Site
São José do Rio Preto, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Três Lagoas, , Brazil
Research Site
Pleven, , Bulgaria
Research Site
Plovdiv, , Bulgaria
Research Site
Plovdiv, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Varna, , Bulgaria
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Kelowna, British Columbia, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Brampton, Ontario, Canada
Research Site
Oshawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, , Canada
Research Site
Santiago, , Chile
Research Site
Santiago, , Chile
Research Site
Santiago, , Chile
Research Site
Temuco, , Chile
Research Site
Viña del Mar, , Chile
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Changchun, , China
Research Site
Changsha, , China
Research Site
Changsha, , China
Research Site
Chengdu, , China
Research Site
Chengdu, , China
Research Site
Chongqing, , China
Research Site
Chongqing, , China
Research Site
Fuzhou, , China
Research Site
Fuzhou, , China
Research Site
Guangzhou, , China
Research Site
Guangzhou, , China
Research Site
Guangzhou, , China
Research Site
Guiyang, , China
Research Site
Hangzhou, , China
Research Site
Hangzhou, , China
Research Site
Hangzhou, , China
Research Site
Kunming, , China
Research Site
Nanchang, , China
Research Site
Nanjing, , China
Research Site
Nanjing, , China
Research Site
Nantong, , China
Research Site
Ningbo, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shengyang, , China
Research Site
Tianjin, , China
Research Site
Wenzhou, , China
Research Site
Wuhan, , China
Research Site
Xi'an, , China
Research Site
Yantai, , China
Research Site
Zhengzhou, , China
Research Site
Zhengzhou, , China
Research Site
Brno, , Czechia
Research Site
Hořovice, , Czechia
Research Site
Hradec Králové, , Czechia
Research Site
Prague, , Czechia
Research Site
Prague, , Czechia
Research Site
Prague, , Czechia
Research Site
Besançon, , France
Research Site
Bordeaux, , France
Research Site
Marseille, , France
Research Site
Montpellier, , France
Research Site
Nice, , France
Research Site
Paris, , France
Research Site
Pierre-Bénite, , France
Research Site
Quimper, , France
Research Site
Rennes, , France
Research Site
Strasbourg, , France
Research Site
Suresnes, , France
Research Site
Villejuif, , France
Research Site
Berlin, , Germany
Research Site
Duisburg, , Germany
Research Site
Hamburg, , Germany
Research Site
Herne, , Germany
Research Site
Mettmann, , Germany
Research Site
Münster, , Germany
Research Site
Nuremberg, , Germany
Research Site
Nürtingen, , Germany
Research Site
Wesel, , Germany
Research Site
Hong Kong, , Hong Kong
Research Site
Hong Kong, , Hong Kong
Research Site
Lai Chi Kok, , Hong Kong
Research Site
Ahmedabad, , India
Research Site
Bangalore, , India
Research Site
Bangalore, , India
Research Site
Delhi, , India
Research Site
Faridabad, , India
Research Site
Kanpur, , India
Research Site
Kolkata, , India
Research Site
Madurai, , India
Research Site
Manipal, , India
Research Site
Meerut, , India
Research Site
Mohali, , India
Research Site
Nagpur, , India
Research Site
New Delhi, , India
Research Site
New Delhi, , India
Research Site
Thiruvananthapuram, , India
Research Site
Varanasi, , India
Research Site
Haifa, , Israel
Research Site
Jerusalem, , Israel
Research Site
Kfar Saba, , Israel
Research Site
Petah Tikva, , Israel
Research Site
Ramat Gan, , Israel
Research Site
Ẕerifin, , Israel
Research Site
Bunkyō City, , Japan
Research Site
Chiba, , Japan
Research Site
Chūōku, , Japan
Research Site
Fukuoka, , Japan
Research Site
Hamamatsu, , Japan
Research Site
Hirakata-shi, , Japan
Research Site
Hirosaki-shi, , Japan
Research Site
Isehara-shi, , Japan
Research Site
Kanazawa, , Japan
Research Site
Kashihara-shi, , Japan
Research Site
Kawagoe-shi, , Japan
Research Site
Kisarazu-shi, , Japan
Research Site
Kita-gun, , Japan
Research Site
Kobe, , Japan
Research Site
Kumamoto, , Japan
Research Site
Kyoto, , Japan
Research Site
Miyazaki, , Japan
Research Site
Morioka, , Japan
Research Site
Nagano, , Japan
Research Site
Nagasaki, , Japan
Research Site
Nagoya, , Japan
Research Site
Nagoya, , Japan
Research Site
Natori-shi, , Japan
Research Site
Osaka, , Japan
Research Site
Osakasayama-shi, , Japan
Research Site
Ota Shi, , Japan
Research Site
Sagamihara-shi, , Japan
Research Site
Sapporo, , Japan
Research Site
Shinjuku-ku, , Japan
Research Site
Toon-shi, , Japan
Research Site
Tsu, , Japan
Research Site
Ube-shi, , Japan
Research Site
Yokohama, , Japan
Research Site
Yokosuka-shi, , Japan
Research Site
Yufu-shi, , Japan
Research Site
Culiacán, , Mexico
Research Site
Culiacán, , Mexico
Research Site
Guadalajara, , Mexico
Research Site
Mexico City, , Mexico
Research Site
Monterrey, , Mexico
Research Site
Monterrey, , Mexico
Research Site
Amsterdam, , Netherlands
Research Site
Hilversum, , Netherlands
Research Site
Roosendaal, , Netherlands
Research Site
The Hague, , Netherlands
Research Site
Tilburg, , Netherlands
Research Site
Utrecht, , Netherlands
Research Site
Callao, , Peru
Research Site
Lima, , Peru
Research Site
Lima, , Peru
Research Site
Lima, , Peru
Research Site
Lima, , Peru
Research Site
Lima, , Peru
Research Site
San Isidro, , Peru
Research Site
Baguio City, , Philippines
Research Site
Cebu City, , Philippines
Research Site
Davao City, , Philippines
Research Site
Iloilo City, , Philippines
Research Site
Quezon City, , Philippines
Research Site
Quezon City, , Philippines
Research Site
San Juan City, , Philippines
Research Site
Bydgoszcz, , Poland
Research Site
Gdansk, , Poland
Research Site
Koszalin, , Poland
Research Site
Lodz, , Poland
Research Site
Olsztyn, , Poland
Research Site
Poznan, , Poland
Research Site
Rzeszów, , Poland
Research Site
Torun, , Poland
Research Site
Warsaw, , Poland
Research Site
Warsaw, , Poland
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Novisibirsk, , Russia
Research Site
Novosibirsk, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Yaroslavl, , Russia
Research Site
Bratislava, , Slovakia
Research Site
Bratislava, , Slovakia
Research Site
Martin, , Slovakia
Research Site
Nitra, , Slovakia
Research Site
Prešov, , Slovakia
Research Site
Šaľa, , Slovakia
Research Site
Trenčín, , Slovakia
Research Site
Cape Town, , South Africa
Research Site
Johannesburg, , South Africa
Research Site
Johannesburg, , South Africa
Research Site
Parow, , South Africa
Research Site
Port Elizabeth, , South Africa
Research Site
Pretoria, , South Africa
Research Site
Daegu, , South Korea
Research Site
Goyang-si, , South Korea
Research Site
Seongnam-si, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Badalona (Barcelona), , Spain
Research Site
Barcelona, , Spain
Research Site
Las Palmas de Gran Canaria, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Oviedo, , Spain
Research Site
Santander, , Spain
Research Site
Seville, , Spain
Research Site
Kaohsiung City, , Taiwan
Research Site
Kaohsiung City, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Tainan, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taoyuan, , Taiwan
Research Site
Bangkok, , Thailand
Research Site
Bangkok, , Thailand
Research Site
Bangkok, , Thailand
Research Site
Chiang Mai, , Thailand
Research Site
Hat Yai, , Thailand
Research Site
Lampang, , Thailand
Research Site
Muang, , Thailand
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Antalya, , Turkey (Türkiye)
Research Site
Eskişehir, , Turkey (Türkiye)
Research Site
Istanbul, , Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Research Site
Kayseri, , Turkey (Türkiye)
Research Site
Cambridge, , United Kingdom
Research Site
Guildford, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Plymouth, , United Kingdom
Research Site
Sutton, , United Kingdom
Research Site
Whitchurch, , United Kingdom
Research Site
Hanoi, , Vietnam
Research Site
Hà Nội, , Vietnam
Research Site
Ho Chi Minh City, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-504998-20-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
2020-000346-33
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
D361BC00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.